Comparison of lipopeptide-based immunocontraceptive vaccines containing different lipid groups

Vaccine

Volumn 25, Issue 1, 2007, Pages 92-101

  Chua, Brendon Y ^a   Zeng, Weiguang ^a   Lau, Yuk Fai ^a   Jackson, David C ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Dendritic cells; Epitope based vaccines; Immunocontraception; Self adjuvanting vaccines; Toll like receptor 2

Indexed keywords

AMINO ACID DERIVATIVE; AMINOCAPROIC ACID; ARGININE; CONTRACEPTIVE VACCINE; DIPALMITOYLGLYCERYLCYSTEINE; EPITOPE; FREUND ADJUVANT; GONADORELIN; GONADORELIN ANTIBODY; GONADORELIN DERIVATIVE; HYBRID PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LAURIC ACID; LAURIC ACID DERIVATIVE; LIPID; LIPOPEPTIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; OCTANOIC ACID; OCTANOIC ACID DERIVATIVE; PALMITIC ACID; SERINE; STEARIC ACID; STEARIC ACID DERIVATIVE; TOLL LIKE RECEPTOR 2;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; CELL ACTIVATION; COMPARATIVE STUDY; CONTRACEPTION; CONTROLLED STUDY; CORRELATION ANALYSIS; DENDRITIC CELL; DRUG EFFICACY; DRUG STRUCTURE; EMBRYO; FEMALE; FEMALE FERTILITY; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOGENICITY; MALE; MEASLES VIRUS; MEASUREMENT; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; UPREGULATION; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES; DENDRITIC CELLS; FEMALE; GONADOTROPIN-RELEASING HORMONE; LIPIDS; LIPOPROTEINS; MICE; MICE, INBRED BALB C; NF-KAPPA B; PEPTIDES; TOLL-LIKE RECEPTOR 2; VACCINES, CONTRACEPTIVE;

EID: 33845197463     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.07.012     Document Type: Article

References (41)

1. Mesa C., and Fernandez L.E. Challenges facing adjuvants for cancer immunotherapy. Immunol Cell Biol 82 6 (2004) 644-650
2. Muhlradt P.F., Kiess M., Meyer H., Sussmuth R., and Jung G. Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration. J Exp Med 185 11 (1997) 1951-1958
3. Deliyannis G., Jackson D.C., Ede N.J., Zeng W., Hourdakis I., Sakabetis E., et al. Induction of long-term memory CD8(+) T cells for recall of viral clearing responses against influenza virus. J Virol 76 9 (2002) 4212-4221
4. Zeng W., Ghosh S., Lau Y.F., Brown L.E., and Jackson D.C. Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J Immunol 169 9 (2002) 4905-4912
5. Chua B.Y., Healy A., Cameron P.U., Stock O., Rizkalla M., Zeng W., et al. Maturation of dendritic cells with lipopeptides that represent vaccine candidates for hepatitis C virus. Immunol Cell Biol 81 1 (2003) 67-72
6. Link C., Gavioli R., Ebensen T., Canella A., Reinhard E., and Guzman C.A. The Toll-like receptor ligand MALP-2 stimulates dendritic cell maturation and modulates proteasome composition and activity. Eur J Immunol 34 3 (2004) 899-907
7. Weigt H., Muhlradt P.F., Emmendorffer A., Krug N., and Braun A. Synthetic mycoplasma-derived lipopeptide MALP-2 induces maturation and function of dendritic cells. Immunobiology 207 3 (2003) 223-233
8. Nishiguchi M., Matsumoto M., Takao T., Hoshino M., Shimonishi Y., Tsuji S., et al. Mycoplasma fermentans lipoprotein M161Ag-induced cell activation is mediated by Toll-like receptor 2: role of N-terminal hydrophobic portion in its multiple functions. J Immunol 166 4 (2001) 2610-2616
9. Morr M., Takeuchi O., Akira S., Simon M.M., and Muhlradt P.F. Differential recognition of structural details of bacterial lipopeptides by toll-like receptors. Eur J Immunol 32 12 (2002) 3337-3347
10. Takeda K., Takeuchi O., and Akira S. Recognition of lipopeptides by Toll-like receptors. J Endotoxin Res 8 6 (2002) 459-463
11. Okusawa T., Fujita M., Nakamura J., Into T., Yasuda M., Yoshimura A., et al. Relationship between structures and biological activities of mycoplasmal diacylated lipopeptides and their recognition by toll-like receptors 2 and 6. Infect Immun 72 3 (2004) 1657-1665
12. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 1 2 (2001) 135-145
13. Kaisho T., and Akira S. Toll-like receptors as adjuvant receptors. Biochim Biophys Acta 1589 1 (2002) 1-13
14. Schjetne K.W., Thompson K.M., Nilsen N., Flo T.H., Fleckenstein B., Iversen J.G., et al. Cutting edge: link between innate and adaptive immunity: Toll-like receptor 2 internalizes antigen for presentation to CD4+ T cells and could be an efficient vaccine target. J Immunol 171 1 (2003) 32-36
15. Ghosh S., and Jackson D.C. Antigenic and immunogenic properties of totally synthetic peptide-based anti-fertility vaccines. Int Immunol 11 7 (1999) 1103-1110
16. Ghosh S., Walker J., and Jackson D.C. Identification of canine helper T-cell epitopes from the fusion protein of canine distemper virus. Immunology 104 1 (2001) 58-66
17. Jackson D.C., Lau Y.F., Le T., Suhrbier A., Deliyannis G., Cheers C., et al. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci USA 101 43 (2004) 15440-15445
18. Zeng W., Gauci S., Ghosh S., Walker J., and Jackson D.C. Characterisation of the antibody response to a totally synthetic immunocontraceptive peptide vaccine based on LHRH. Vaccine 23 35 (2005) 4427-4435
19. Delves P.J., Lund T., and Roitt I.M. Antifertility vaccines. Trends Immunol 23 4 (2002) 213-219
20. Oonk H.B., Turkstra J.A., Schaaper W.M., Erkens J.H., Schuitemaker-de Weerd M.H., van Nes A., et al. New GnRH-like peptide construct to optimize efficient immunocastration of male pigs by immunoneutralization of GnRH. Vaccine 16 11-12 (1998) 1074-1082
21. Ferro V.A., and Stimson W.H. Immunoneutralisation of gonadotrophin releasing hormone: a potential treatment for oestrogen-dependent breast cancer. Eur J Cancer 33 9 (1997) 1468-1478
22. Talwar G.P. Vaccines and passive immunological approaches for the control of fertility and hormone-dependent cancers. Immunol Rev 171 (1999) 173-192
23. Winzler C., Rovere P., Rescigno M., Granucci F., Penna G., Adorini L., et al. Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures. J Exp Med 185 2 (1997) 317-328
24. Fitzgerald K.A., Palsson-McDermott E.M., Bowie A.G., Jefferies C.A., Mansell A.S., Brady G., et al. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature 413 6851 (2001) 78-83
25. Muhlradt P.F., Kiess M., Meyer H., Sussmuth R., and Jung G. Structure and specific activity of macrophage-stimulating lipopeptides from Mycoplasma hyorhinis. Infect Immun 66 10 (1998) 4804-4810
26. Fitzmaurice C.J., Brown L.E., Kronin V., and Jackson D.C. The geometry of synthetic peptide-based immunogens affects the efficiency of T cell stimulation by professional antigen-presenting cells. Int Immunol 12 4 (2000) 527-535
27. BenMohamed L., Belkaid Y., Loing E., Brahimi K., Gras-Masse H., and Druilhe P. Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant. Eur J Immunol 32 8 (2002) 2274-2281
28. BenMohamed L., Krishnan R., Auge C., Primus J.F., and Diamond D.J. Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology 106 1 (2002) 113-121
29. Le Gal F.A., Prevost-Blondel A., Lengagne R., Bossus M., Farace F., Chaboissier A., et al. Lipopeptide-based melanoma cancer vaccine induced a strong MART-27-35-cytotoxic T lymphocyte response in a preclinal study. Int J Cancer 98 2 (2002) 221-227
30. Nardin E.H., Calvo-Calle J.M., Oliveira G.A., Clavijo P., Nussenzweig R., Simon R., et al. Plasmodium falciparum polyoximes: highly immunogenic synthetic vaccines constructed by chemoselective ligation of repeat B-cell epitopes and a universal T-cell epitope of CS protein. Vaccine 16 6 (1998) 590-600
31. Obert M., Pleuger H., Hanagarth H.G., Schulte-Monting J., Wiesmuller K.H., Braun D.G., et al. Protection of mice against SV40 tumours by Pam3Cys, MTP-PE and Pam3Cys conjugated with the SV40 T antigen-derived peptide, K(698)-T(708). Vaccine 16 2-3 (1998) 161-169
32. Zeng W., Jackson D.C., Murray J., Rose K., and Brown L.E. Totally synthetic lipid-containing polyoxime peptide constructs are potent immunogens. Vaccine 18 11-12 (2000) 1031-1039
33. Nardelli B., Haser P.B., and Tam J.P. Oral administration of an antigenic synthetic lipopeptide (MAP-P3C) evokes salivary antibodies and systemic humoral and cellular responses. Vaccine 12 14 (1994) 1335-1339
34. Mora A.L., and Tam J.P. Controlled lipidation and encapsulation of peptides as a useful approach to mucosal immunizations. J Immunol 161 7 (1998) 3616-3623
35. Rharbaoui F., Drabner B., Borsutzky S., Winckler U., Morr M., Ensoli B., et al. The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant. Eur J Immunol 32 10 (2002) 2857-2865
36. Borsutzky S., Fiorelli V., Ebensen T., Tripiciano A., Rharbaoui F., Scoglio A., et al. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant. Eur J Immunol 33 6 (2003) 1548-1556
37. Shimizu T., Ohtsuka Y., Yanagihara Y., Kurimura M., Takemoto M., and Achiwa K. Comparison of biologic activities of synthetic lipopentapeptide analogs of bacterial lipoprotein in mice. Mol Biother 3 1 (1991) 46-50
38. Jackson D.C., Deliyannis G., Eriksson E., Dinatale I., Rizkalla M., and Gowans E.J. Dendritic cell immunotherapy of hepatitis C virus infection: toxicology of lipopeptide-loaded dendritic cells. Int J Pep Res Therapeutics 11 (2005) 223-235
39. Lee J.Y., Zhao L., Youn H.S., Weatherill A.R., Tapping R., Feng L., et al. Saturated fatty acid activates but polyunsaturated fatty acid inhibits Toll-like receptor 2 dimerized with Toll-like receptor 6 or 1. J Biol Chem 279 17 (2004) 16971-16979
40. Takeuchi O., Sato S., Horiuchi T., Hoshino K., Takeda K., Dong Z., et al. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 169 1 (2002) 10-14
41. Fifis T., Gamvrellis A., Crimeen-Irwin B., Pietersz G.A., Li J., Mottram P.L., et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol 173 5 (2004) 3148-3154